Hematological features and alternate diagnoses in critically ill thrombotic antiphospholipid syndrome patients.
ADAMTS13
Antiphospholipid syndrome
Catastrophic antiphospholipid syndrome
Heparin-induced thrombocytopenia
Intensive care unit
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
29 Jul 2024
29 Jul 2024
Historique:
received:
12
03
2024
accepted:
26
06
2024
revised:
14
05
2024
medline:
29
7
2024
pubmed:
29
7
2024
entrez:
29
7
2024
Statut:
aheadofprint
Résumé
Severe thrombotic antiphospholipid syndrome (APS) frequently affects the kidney, heart, and central nervous system. The precise frequency, clinical picture, differential diagnoses, and outcome of APS-related hematological involvement are lacking, especially in patients requiring ICU admission. This study aimed to describe the hematological manifestations associated with critically ill thrombotic APS patients and catastrophic antiphospholipid syndrome. This French, national, multicenter, retrospective study, conducted, from January 2000 to September 2018, included all APS patients admitted to 24 participating centers' ICUs with any new thrombotic manifestation. The prevalence of hematological manifestations and their associated outcomes were studied. One hundred and thirty-four patients, female 72%, median [IQR] age 45 [34-56] years, with 152 episodes were included. Anemia was present in 95% of episodes and thrombocytopenia in 93%. The lowest values for hemoglobin and platelets were 7.1 [6.3-8.8] g/dL and 38 [21-60] g/L, respectively. The lowest platelet count below 20 g/L was significantly associated with a higher in-ICU mortality rate (50%, p < 0.0001). A thrombotic microangiopathy syndrome (TMA) syndrome was seen in 16 patients (12%) and was associated with higher in-hospital mortality (p = 0.05). Median ADAMTS-13 levels were 44% [27-74]. Anti-ADAMTS13 antibodies were tested in 11 patients and found negative in all. A suspicion of heparin-induced thrombocytopenia (HIT) was raised in 66 patients but only four patients were classified as definite HIT. Disseminated intravascular coagulation (DIC) was seen in 51% of patients. Thrombocytopenia is very frequent in severe APS patients and may be related to TMA, HIT, or DIC. Deciphering the mechanisms of thrombocytopenia is decisive in CAPS patients. Key Points • Thrombocytopenia is the hallmark laboratory finding in CAPS. • A complete thrombotic microangiopathy pattern is infrequent in CAPS patients. • Alternate diagnoses of CAPS, especially heparin-induced thrombocytopenia, need to be adequately investigated.
Identifiants
pubmed: 39073513
doi: 10.1007/s10067-024-07051-x
pii: 10.1007/s10067-024-07051-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
Références
Garcia D, Erkan D (2018) Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 378:2010–2021. https://doi.org/10.1056/NEJMra1705454
doi: 10.1056/NEJMra1705454
pubmed: 29791828
Pineton de Chambrun M, Larcher R, Pène F, Argaud L, Demoule A, Jamme M, Coudroy R, Mathian A, Gibelin A, Azoulay E, Tandjaoui-Lambiotte Y, Dargent A, Beloncle F-M, Raphalen J-H, Couteau-Chardon A, de Prost N, Devaquet J, Contou D, Gaugain S, Trouiller P, Grangé S, Ledochowski S, Lemarie J, Faguer S, Degos V, Combes A, Luyt C-E, Amoura Z (2019) CAPS criteria fail to identify most severely-ill thrombotic antiphospholipid syndrome patients requiring intensive care unit admission. J Autoimmun 103:102292. https://doi.org/10.1016/j.jaut.2019.06.003
doi: 10.1016/j.jaut.2019.06.003
pubmed: 31253464
Pineton de Chambrun M, Larcher R, Pène F, Argaud L, Mayaux J, Jamme M, Coudroy R, Mathian A, Gibelin A, Azoulay E, Tandjaoui-Lambiotte Y, Dargent A, Beloncle F-M, Raphalen J-H, Couteau-Chardon A, de Prost N, Devaquet J, Contou D, Gaugain S, Trouiller P, Grangé S, Ledochowski S, Lemarie J, Faguer S, Degos V, Luyt C-E, Combes A, Amoura Z (2020) In-hospital mortality-associated factors in patients with thrombotic antiphospholipid syndrome requiring ICU admission. Chest 157:1158–1166. https://doi.org/10.1016/j.chest.2019.11.010
doi: 10.1016/j.chest.2019.11.010
pubmed: 31783015
Cervera R, Piette J-C, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RHWM, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris J-C, Quéré I, Hachulla E, Vasconcelos C, Roch B, Fernández-Nebro A, Boffa M-C, Hughes GRV, Ingelmo M (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients: clinical and immunologic manifestations of APS. Arthritis Rheum 46:1019–1027. https://doi.org/10.1002/art.10187
doi: 10.1002/art.10187
pubmed: 11953980
Rodríguez-Pintó I, Moitinho M, Santacreu I, Shoenfeld Y, Erkan D, Espinosa G, Cervera R (2016) Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the international CAPS registry. Autoimmun Rev 15:1120–1124. https://doi.org/10.1016/j.autrev.2016.09.010
doi: 10.1016/j.autrev.2016.09.010
pubmed: 27639837
Asherson RA, Cervera R, Piette J-C, Font J, Lie JT, Burcoglu A, Lim K, Muñoz-Rodríguez FJ, Levy RA, Boué F, Rossert J, Ingelmo M (1998) Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. Med (Baltimore) 77:195–207. https://doi.org/10.1097/00005792-199805000-00005
doi: 10.1097/00005792-199805000-00005
Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa M-C, Piette J-C, Khamashta MA, Shoenfeld Y (2003) Catastrophic antiphospholipid syndrome registry project group, catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12:530–534. https://doi.org/10.1191/0961203303lu394oa
doi: 10.1191/0961203303lu394oa
pubmed: 12892393
Cervera R (2005) Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 64:1205–1209. https://doi.org/10.1136/ard.2004.025759
doi: 10.1136/ard.2004.025759
pubmed: 15708888
pmcid: 1755612
Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette J-C, Brey R, Derksen R, Harris EN, Hughes GRV, Triplett DA, Khamashta MA (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311. https://doi.org/10.1002/1529-0131(199907)42:7%3c1309::AID-ANR1%3e3.0.CO;2-F
doi: 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
pubmed: 10403256
Lockshin MD, Sammaritano LR, Schwartzman S (2000) Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 43:440. https://doi.org/10.1002/1529-0131(200002)43:2%3c440::AID-ANR26%3e3.0.CO;2-N
doi: 10.1002/1529-0131(200002)43:2<440::AID-ANR26>3.0.CO;2-N
pubmed: 10693886
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RHWM, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306. https://doi.org/10.1111/j.1538-7836.2006.01753.x
doi: 10.1111/j.1538-7836.2006.01753.x
pubmed: 16420554
Amigo M-C, Goycochea-Robles MV, Espinosa-Cuervo G, Medina G, Barragán-Garfias JA, Vargas A, Jara LJ (2015) Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS). Lupus 24:927–934. https://doi.org/10.1177/0961203315576858
doi: 10.1177/0961203315576858
pubmed: 25767071
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR (2019) European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 71(2019):1400–1412. https://doi.org/10.1002/art.40930
doi: 10.1002/art.40930
pubmed: 31385462
pmcid: 6827566
Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P, Girma J-P, Azoulay E, Brun-Buisson C, Fakhouri F, Mira J-P, Oksenhendler E, Poullin P, Rondeau E, Schleinitz N, Schlemmer B, Teboul J-L, Vanhille P, Vernant J-P, Meyer D, Veyradier A (2007) for the French and clinical biological network on adult thrombotic microangiopathies, prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity. Blood 109:2815–2822. https://doi.org/10.1182/blood-2006-02-006064
doi: 10.1182/blood-2006-02-006064
pubmed: 17164349
Cuker A, Tseng EK, Nieuwlaat R, Angchaisuksiri P, Blair C, Dane K, Davila J, DeSancho MT, Diuguid D, Griffin DO, Kahn SR, Klok FA, Lee AI, Neumann I, Pai A, Pai M, Righini M, Sanfilippo KM, Siegal D, Skara M, Touri K, Akl EA, BouAkl I, Boulos M, Brignardello-Petersen R, Charide R, Chan M, Dearness K, Darzi AJ, Kolb P, Colunga-Lozano LE, Mansour R, Morgano GP, Morsi RZ, Noori A, Piggott T, Qiu Y, Roldan Y, Schünemann F, Stevens A, Solo K, Ventresca M, Wiercioch W, Mustafa RA, Schünemann HJ, American society of hematology (2021) Guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv 5(2021):872–888. https://doi.org/10.1182/bloodadvances.2020003763
doi: 10.1182/bloodadvances.2020003763
pubmed: 33560401
pmcid: 7869684
Levi M, Scully M (2018) How I treat disseminated intravascular coagulation. Blood 131:845–854. https://doi.org/10.1182/blood-2017-10-804096
doi: 10.1182/blood-2017-10-804096
pubmed: 29255070
Asherson RA (2005) Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. Ann Rheum Dis 64:943–946. https://doi.org/10.1136/ard.2004.026377
doi: 10.1136/ard.2004.026377
pubmed: 15897312
pmcid: 1755506
Levi M, Toh CH, Thachil J, Watson HG (2009) Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol 145:24–33. https://doi.org/10.1111/j.1365-2141.2009.07600.x
doi: 10.1111/j.1365-2141.2009.07600.x
pubmed: 19222477
Coppo P, Veyradier A (2005) Microangiopathies thrombotiques: physiopathologie, diagnostic et traitement. Réanimation 14:594–603. https://doi.org/10.1016/j.reaurg.2005.10.008
doi: 10.1016/j.reaurg.2005.10.008
Rieger M (2005) ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 106:1262–1267. https://doi.org/10.1182/blood-2004-11-4490
doi: 10.1182/blood-2004-11-4490
pubmed: 15890682
Yelnik CM, Miranda S, Mékinian A, Lazaro E, Quéméneur T, Provot F, Frimat M, Morell-Dubois S, Le Guern V, Hachulla E, Costedoat-Chalumeau N, Lambert M (2020) Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab. Blood 136:2473–2477. https://doi.org/10.1182/blood.2020007499
doi: 10.1182/blood.2020007499
pubmed: 32722806
Faguer S, Ribes D (2022) Early use of eculizumab for catastrophic antiphospholipid syndrome. Br J Haematol 196:2. https://doi.org/10.1111/bjh.17783
doi: 10.1111/bjh.17783